PMID- 30842034
OWN - NLM
STAT- MEDLINE
DCOM- 20191107
LR  - 20191107
IS  - 1879-0070 (Electronic)
IS  - 0732-8893 (Linking)
VI  - 94
IP  - 3
DP  - 2019 Jul
TI  - Micafungin prophylaxis in routine medical practice in adult and pediatric 
      patients with hematological malignancy: a prospective, observational study in 
      France.
PG  - 268-273
LID - S0732-8893(18)30421-8 [pii]
LID - 10.1016/j.diagmicrobio.2019.01.011 [doi]
AB  - This prospective, observational, multicenter study evaluated the real-world 
      incidence of invasive fungal infection (IFI) during and after micafungin 
      prophylaxis in France. Patients with a hematological malignancy/solid tumor 
      received micafungin prophylaxis according to usual clinical practice and were 
      followed for 3 months. Primary endpoint was breakthrough IFI incidence during 
      prophylaxis. Secondary endpoints included the identification of IFI risk factors, 
      IFI incidence during follow-up, and adverse events (AEs). One hundred and fifty 
      patients (55 children, 95 adults) were enrolled. Micafungin prophylaxis was 
      initiated at 50 mg in adults and at a median 1.01 mg/kg (range: 0.6-2.2) in 
      children. Fifteen patients (10%) experienced an IFI during prophylaxis. IFI 
      breakthrough occurred in 15% children, 7% adults, 3.1% allogeneic transplant 
      patients, 8.7% acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) 
      patients, 7.0% other patients (never allotransplanted/non-AML/MDS). Nineteen 
      patients (12.7%) experienced an IFI during 3-month follow-up. Micafungin was well 
      tolerated with few treatment-related AEs, supporting its use in this patient 
      population in France.
CI  - Copyright (c) 2019 The Authors. Published by Elsevier Inc. All rights reserved.
FAU - El Cheikh, Jean
AU  - El Cheikh J
AD  - Institut Paoli-Calmettes, Marseille, France. Electronic address: je46@aub.edu.lb.
FAU - Ceballos, Patrice
AU  - Ceballos P
AD  - Hopital Sant Eloi, Montpellier, France.
FAU - Dalle, Jean-Hugues
AU  - Dalle JH
AD  - Hopital Robert Debre, Assistance-Publique-Hopitaux de Paris et Universite Paris 7 
      - Paris-Diderot, Paris, France.
FAU - Ducastelle-Lepretre, Sophie
AU  - Ducastelle-Lepretre S
AD  - Centre Hospitalier Lyon Sud, Pierre-Benite, France.
FAU - Dulon, Elsa
AU  - Dulon E
AD  - Astellas Pharma, Levallois-Perret, France.
FAU - Herbrecht, Raoul
AU  - Herbrecht R
AD  - Hopitaux Universitaires de Strasbourg and Universite de Strasbourg, Inserm, 
      UMR-S1113/IRFAC, Strasbourg, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Observational Study
DEP - 20190126
PL  - United States
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
RN  - 0 (Antifungal Agents)
RN  - R10H71BSWG (Micafungin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Antifungal Agents/*administration & dosage
MH  - Chemoprevention/*methods
MH  - Child
MH  - Child, Preschool
MH  - Drug-Related Side Effects and Adverse Reactions/epidemiology/pathology
MH  - Female
MH  - France/epidemiology
MH  - Hematologic Neoplasms/*complications
MH  - Humans
MH  - Incidence
MH  - Infant
MH  - Invasive Fungal Infections/*epidemiology/*prevention & control
MH  - Longitudinal Studies
MH  - Male
MH  - Micafungin/*administration & dosage
MH  - Middle Aged
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Invasive fungal infection
OT  - Micafungin, hematology
OT  - Prophylaxis
OT  - Prospective, observational, multicenter study
EDAT- 2019/03/08 06:00
MHDA- 2019/11/08 06:00
CRDT- 2019/03/08 06:00
PHST- 2018/10/17 00:00 [received]
PHST- 2019/01/16 00:00 [revised]
PHST- 2019/01/21 00:00 [accepted]
PHST- 2019/03/08 06:00 [pubmed]
PHST- 2019/11/08 06:00 [medline]
PHST- 2019/03/08 06:00 [entrez]
AID - S0732-8893(18)30421-8 [pii]
AID - 10.1016/j.diagmicrobio.2019.01.011 [doi]
PST - ppublish
SO  - Diagn Microbiol Infect Dis. 2019 Jul;94(3):268-273. doi: 
      10.1016/j.diagmicrobio.2019.01.011. Epub 2019 Jan 26.